Redhill Biopharma Ltd
RDHL1.150USD
-0.035-2.95%
收盤 12/24, 13:00（美東）報價延遲15分鐘
3.83M總市值
0.02本益比TTM
關於 Redhill Biopharma Ltd 公司
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Redhill Biopharma Ltd簡介
公司代碼RDHL
公司名稱Redhill Biopharma Ltd
上市日期Feb 01, 2011
CEOBen-Asher (Dror)
員工數量35
證券類型Depository Receipt
年結日Feb 01
公司地址21 Ha'arba'a St.
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編6473921
電話97235413131
網址https://www.redhillbio.com/
公司代碼RDHL
上市日期Feb 01, 2011
CEOBen-Asher (Dror)
Redhill Biopharma Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Gagnon Securities LLC
0.35%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
其他
99.55%
持股股東
持股股東
佔比
Gagnon Securities LLC
0.35%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
其他
99.55%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
0.40%
Research Firm
0.08%
Investment Advisor
0.04%
其他
99.48%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
38
103.50K
3.11%
-21.59K
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
2023Q2
113
26.79K
29.96%
+840.00
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Desjardins Securities Inc.
3.39K
0.1%
--
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
1.77K
0.05%
+380.00
+27.38%
Jun 30, 2025
BofA Global Research (US)
303.00
0.01%
--
--
Jun 30, 2025
GAMMA Investing LLC
135.00
0%
-1.93K
-93.45%
Sep 30, 2025
SBI Securities Co., Ltd.
2.00K
0.06%
+2.00K
+39980.00%
Jun 30, 2025
UBS Switzerland AG
1.00
0%
--
--
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
公告日期
類型
比率
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
常見問題
Redhill Biopharma Ltd的前五大股東是誰？
Redhill Biopharma Ltd的前五大股東如下：
Desjardins Securities Inc.持有股份：3.39K佔總股份比例：0.10%。
Rhumbline Advisers Ltd. Partnership持有股份：1.77K佔總股份比例：0.05%。
BofA Global Research (US)持有股份：303.00佔總股份比例：0.01%。
GAMMA Investing LLC持有股份：135.00佔總股份比例：0.00%。
SBI Securities Co., Ltd.持有股份：2.00K佔總股份比例：0.06%。
Desjardins Securities Inc.持有股份：3.39K佔總股份比例：0.10%。
Rhumbline Advisers Ltd. Partnership持有股份：1.77K佔總股份比例：0.05%。
BofA Global Research (US)持有股份：303.00佔總股份比例：0.01%。
GAMMA Investing LLC持有股份：135.00佔總股份比例：0.00%。
SBI Securities Co., Ltd.持有股份：2.00K佔總股份比例：0.06%。
Redhill Biopharma Ltd的前三大股東類型是什麼？
Redhill Biopharma Ltd 的前三大股東類型分別是：
Gagnon Securities LLC
Desjardins Securities Inc.
Rhumbline Advisers Ltd. Partnership
Gagnon Securities LLC
Desjardins Securities Inc.
Rhumbline Advisers Ltd. Partnership
有多少機構持有Redhill Biopharma Ltd(RDHL)的股份？
截至2025Q3，共有38家機構持有Redhill Biopharma Ltd的股份，合計持有的股份價值約為103.50K，占公司總股份的3.11% 。與2025Q2相比，機構持股有所增加，增幅為-1.28%。
哪個業務部門對Redhill Biopharma Ltd的收入貢獻最大？
在--，--業務部門對Redhill Biopharma Ltd的收入貢獻最大，創收--，占總收入的--% 。
